RT Journal Article
SR Electronic
T1 Digestive Manifestations in Patients Hospitalized with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.07.20143024
DO 10.1101/2020.07.07.20143024
A1 B. Joseph Elmunzer
A1 Rebecca L. Spitzer
A1 Lydia D. Foster
A1 Ambreen A. Merchant
A1 Eric F. Howard
A1 Vaishali A. Patel
A1 Mary K. West
A1 Emad Qayed
A1 Rosemary Nustas
A1 Ali Zakaria
A1 Marc S. Piper
A1 Jason R. Taylor
A1 Lujain Jaza
A1 Nauzer Forbes
A1 Millie Chau
A1 Luis F. Lara
A1 Georgios I. Papachristou
A1 Michael L. Volk
A1 Liam G. Hilson
A1 Selena Zhou
A1 Vladimir M. Kushnir
A1 Alexandria M. Lenyo
A1 Caroline G. McLeod
A1 Sunil Amin
A1 Gabriela N. Kuftinec
A1 Dhiraj Yadav
A1 Charlie Fox
A1 Jennifer M. Kolb
A1 Swati Pawa
A1 Rishi Pawa
A1 Andrew Canakis
A1 Christopher Huang
A1 Laith H. Jamil
A1 Andrew M. Aneese
A1 Benita K. Glamour
A1 Zachary L Smith
A1 Katherine A. Hanley
A1 Jordan Wood
A1 Harsh K. Patel
A1 Janak N. Shah
A1 Emil Agarunov
A1 Amrita Sethi
A1 Evan L. Fogel
A1 Gail McNulty
A1 Abdul Haseeb
A1 Judy A. Trieu
A1 Rebekah E. Dixon
A1 Jeong Yun Yang
A1 Robin B. Mendelsohn
A1 Delia Calo
A1 Olga C. Aroniadis
A1 Joseph F. LaComb
A1 James M. Scheiman
A1 Bryan G. Sauer
A1 Duyen T. Dang
A1 Cyrus R. Piraka
A1 Eric D. Shah
A1 Heiko Pohl
A1 William M. Tierney
A1 Stephanie Mitchell
A1 Ashwinee Condon
A1 Adrienne Lenhart
A1 Kulwinder S. Dua
A1 Vikram S. Kanagala
A1 Ayesha Kamal
A1 Vikesh K. Singh
A1 Maria Ines Pinto-Sanchez
A1 Joy M. Hutchinson
A1 Richard S. Kwon
A1 Sheryl J. Korsnes
A1 Harminder Singh
A1 Zahra Solati
A1 Amar R. Deshpande
A1 Don C. Rockey
A1 Teldon B. Alford
A1 Valerie Durkalski
A1 the North American Alliance for the Study of Digestive Manifestations of COVID-19
YR 2020
UL http://medrxiv.org/content/early/2020/07/09/2020.07.07.20143024.abstract
AB Background The prevalence and significance of digestive manifestations in COVID-19 remain uncertain.Methods Consecutive patients hospitalized with COVID-19 were identified across a geographically diverse alliance of medical centers in North America. Data pertaining to baseline characteristics, symptomatology, laboratory assessment, imaging, and endoscopic findings from the time of symptom onset until discharge or death were manually abstracted from electronic health records to characterize the prevalence, spectrum, and severity of digestive manifestations. Regression analyses were performed to evaluate the association between digestive manifestations and severe outcomes related to COVID-19.Results A total of 1992 patients across 36 centers met eligibility criteria and were included. Overall, 53% of patients experienced at least one gastrointestinal symptom at any time during their illness, most commonly diarrhea (34%), nausea (27%), vomiting (16%), and abdominal pain (11%). In 74% of cases, gastrointestinal symptoms were judged to be mild. In total, 35% of patients developed an abnormal alanine aminotransferase or total bilirubin level; these were elevated to less than 5 times the upper limit of normal in 77% of cases. After adjusting for potential confounders, the presence of gastrointestinal symptoms at any time (odds ratio 0.93, 95% confidence interval 0.76-1.15) or liver test abnormalities on admission (odds ratio 1.31, 95% confidence interval 0.80-2.12) were not independently associated with mechanical ventilation or death.Conclusions Among patients hospitalized with COVID-19, gastrointestinal symptoms and liver test abnormalities were common but the majority were mild and their presence was not associated with a more severe clinical course.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis was an observational studyFunding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review board approval was obtained at each center prior to patient identification and data collection.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll authors had access the data